Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $54.94B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: SRE stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at SRE's multiple
Needs EPS (TTM) is negative, SRE P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRE FY 2025 (ended Dec 31, 2025) · VNDA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 62% equity / 38% debt · EV / Revenue 6.43x · EV / EBITDA 13.46x
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
SRE carries the larger enterprise value at $88.05B against $321.69M; VNDA trades on the lower EV / Revenue multiple (1.49x vs 6.43x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SEMPRA · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.05x
0.24x
Net debt / EBITDA
Leverage against operating earnings
5.06x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$29.00M
$84.85M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DOMINION ENERGY, INC
SRE vs D
WILLIAMS COMPANIES, INC.
SRE vs WMB
ATMOS ENERGY CORP
SRE vs ATO
ONE Gas, Inc.
SRE vs OGS
NATIONAL FUEL GAS CO
SRE vs NFG
SUPERNUS PHARMACEUTICALS, INC.
SRE vs SUPN
CATALYST PHARMACEUTICALS, INC.
SRE vs CPRX
Harmony Biosciences Holdings, Inc.
SRE vs HRMY
ELI LILLY & Co
SRE vs LLY
INCYTE CORP
SRE vs INCY
Sarepta Therapeutics, Inc.
SRE vs SRPT
$33.15B
$78.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
